Mahzi Therapeutics Doses First Patient in Groundbreaking Gene Therapy Trial for Pitt Hopkins Syndrome
核心洞察
Mahzi Therapeutics (搜索) has dosed the first patient in its Phase 1/2 UNITE study of MZ-1866 (搜索), marking the first investigational gene therapy trial for Pitt Hopkins syndrome (搜索).
The global, multicenter trial will evaluate the safety and preliminary efficacy of a single intracerebroventricular administration of MZ-1866 (搜索) in approximately 12 participants with genetically confirmed Pitt Hopkins syndrome (搜索).
Pitt Hopkins syndrome (搜索) affects approximately 1 in 34,000-41,000 individuals, with an estimated 8,000 people living with the condition in the United States.
Mahzi Therapeutics (搜索) has achieved a significant milestone by dosing the first patient in its Phase 1/2 UNITE study evaluating MZ-1866 (搜索), an investigational gene therapy for Pitt Hopkins syndrome (搜索). This marks the first gene therapy trial specifically targeting this rare neurogenetic disorder, representing a historic breakthrough for the patient community.
Trial Design and Objectives
The Phase 1/2 UNITE clinical trial is a global, multicenter, open-label study designed to assess the safety, tolerability, and preliminary efficacy of a single administration of MZ-1866 (搜索) in participants with genetically confirmed Pitt Hopkins syndrome (搜索). The study aims to enroll approximately 12 participants across 5 sites in the United States, Israel, and Spain.
Participants will receive a single dose of MZ-1866 (搜索) delivered via intracerebroventricular administration. In addition to its primary safety objectives, the trial will evaluate developmental, communication, cognitive, and motor function exploratory endpoints.
Understanding Pitt Hopkins Syndrome
Pitt Hopkins syndrome (搜索) is a rare condition affecting approximately 1 in 34,000-41,000 individuals, translating to an estimated 8,000 people living with the condition in the United States. The syndrome results from mutations in the TCF4 (搜索) gene and presents with a complex constellation of symptoms.
Affected individuals typically present with a combination of autism (搜索), developmental delay, hypotonia, ataxia, apnea/hyperventilation, severe gastrointestinal issues, and, less frequently, epilepsy (搜索). These symptoms create significant challenges for patients and their families, highlighting the urgent need for effective therapeutic interventions.
MZ-1866: Targeting the Root Cause
MZ-1866 (搜索) is a novel AAV9-TCF4 (搜索) gene replacement therapy, constructed by inserting TCF4 isoform B (the longest known isoform and one of the most abundant brain isoforms) into an AAV9 expression cassette under the regulation of multimer E box sequences. The therapy aims to address the underlying disease biology by providing functional copies of the TCF4 gene.
This approach represents a fundamental shift from symptomatic treatment to addressing the genetic root cause of the disorder, potentially offering more comprehensive therapeutic benefits for patients.
Industry and Community Response
"Dosing the first patient is a significant achievement for the MZ-1866 (搜索) program and for Mahzi's evolution as a clinical-stage company," said Yael Weiss, M.D., Ph.D., Chief Executive Officer of Mahzi. "We look forward to advancing this program to address a significant unmet medical need for patients with Pitt Hopkins syndrome (搜索) and their families."
The patient advocacy community has expressed significant enthusiasm for this development. "The launch of the first investigational gene therapy trial for Pitt Hopkins syndrome (搜索) represents a truly historic milestone for our community," said Audrey Davidow, President of the Pitt Hopkins Research Foundation (搜索). "For families who have waited years for meaningful therapeutic progress, this moment reflects countless hours of advocacy, collaboration, and perseverance. This Phase 1/2 trial brings long-held hope closer to reality and marks a critical step toward transforming the future of care for individuals living with Pitt Hopkins."
Collaborative Development and Funding
MZ-1866 (搜索) was developed in collaboration with the Muotri Lab at the University of California San Diego, demonstrating the importance of academic-industry partnerships in advancing rare disease research. The Phase 1/2 study was made possible by funding from the California Institute for Regenerative Medicine (搜索) (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research (Grant Number TRAN1-13997).
This collaborative approach highlights the multi-stakeholder effort required to bring innovative therapies for rare diseases from laboratory to clinic, involving biotechnology companies, academic researchers, patient advocacy organizations, and state funding agencies.